By: IPP Bureau
Last updated : May 21, 2026 7:34 am
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has posed highest-ever quarterly revenue alongside strong growth in profitability for its financial results for the quarter and year ended March 31, 2026.
For Q4 FY26, the company reported revenue from operations of Rs. 619.5 crore, up 17.4 per cent year-on-year from Rs. 527.8 crore in the corresponding quarter last year.
EBITDA rose 39.8 per cent to Rs. 94.3 crore compared to Rs. 67.5 crore in Q4 FY25, while EBITDA margin expanded by 251 basis points to 15.2 per cent.
Profit after tax (PAT) for the quarter increased 68.2 per cent to Rs. 53.2 crore against Rs. 31.6 crore in the year-ago period, with PAT margin improving to 8.6 per cent from 5.9 per cent.
For the full financial year FY26, revenue from operations stood at Rs. 2,319.1 crore, registering an 11.5 per cent increase over Rs. 2,079.2 crore in FY25. EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore.
Vikas Gupta, Joint Managing Director, IOCL said, “Pharmaceuticals segment continued to witness robust growth led by increasing contribution from the non-Ibuprofen portfolio, with products such as Paracetamol, Metformin and other APIs witnessing healthy traction.”
“The improving product mix, combined with IOL’s position as one of the lowest-cost producers in key molecules, supported stronger profitability and margin expansion in the Pharma segment,” added Gupta.